J. Weissenburger et al., Electrophysiological effects of cetirizine, astemizole and D-sotalol in a canine model of long QT syndrome, CLIN EXP AL, 29, 1999, pp. 190-196
Observations of torsades de pointes during therapy with terfenadine and ast
emizole has raised concern about the cardiac safety of non-sedating H-1-ant
agonist agents. We compared cetirizine, another compound of that class, to
D-sotalol and to astemizole in a model of acquired long QT syndrome.
Open-chest surgery was performed in adult beagle dogs anaesthetized with ha
lothane and thiopental. Bradycardia was produced with beta-adrenergic block
ade and sinus node crush. Four left ventricular intramyocardial unipolar mo
nophasic action potentials (MAP) were recorded during atrial pacing at basi
c cycle lengths (BCL) 300-1500 msec, before and during three successive l-h
drug infusions (0.14, 0.45 and 1.4 mg/kg/h for astemizole and cetirizine a
nd 1.1, 2.2 and 4.5 mg/kg/h for D-sotalol).
Dose- and bradycardia-dependent prolongations of MAP duration (MAPD) were p
roduced by D-sotalol (P<0.001) and astemizole (P<0.001) but not by cetirizi
ne. At BCL 1500 ms, the three infusions of astemizole prolonged endocardial
MAPD from 323 +/- 8 msec (mean +/- SE) at baseline to 343 +/- 10, 379 +/-
13 and 468 +/- 26 msec, respectively (n = 9. Sotalol prolonged that MAPD fr
om 339 +/- 6 msec to 377 +/- 7, 444 +/- 15 and 485 +/- 24 msec (n = 7). In
contrast, cetirizine did not prolong MAPD: 341 +/- 8 msec at baseline Vs 33
0 +/- 8, 324 +/- 9 and 323 +/- 11 msec (n=9). Drug-induced increase in tran
smural dispersion reached +79 +/- 19 msec after astemizole, +59 +/- 21 msec
after D-sotalol and only +7 +/- 11 msec after cetirizine. Runs of ventricu
lar tachycardias and torsades de pointes occurred during dose three of aste
mizole (5/9 dogs) and D-sotalol (4/7 dogs) but never during cetirizine.
In the present model, astemizole and D-sotalol but not cetirizine prolonged
MAPD and transmural dispersions of repolarization and produced torsades de
pointes. These results suggest that the halothane-anaesthetized bradycardi
c dog could be a valuable model to discriminate drugs for their class III e
ffects and proarrhythmic potencies.